Compare Roundhill Magnificent Seven ETF (MAGS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Roundhill Magnificent Seven ETF trades at $71.97 (market cap $5.89B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Roundhill Magnificent Seven ETF is the larger of the two by market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Magnificent Seven ETF for 35 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MAGS | TVTX | |
|---|---|---|
Market Cap | $5.89B | $4.88B |
Volume | 3,080,349 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $74.30 | $67.52 |
52-Week Low | $55.39 | $26.79 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS, the Roundhill Magnificent Seven ETF, trades at $74.30, up 0.43% on the day, with a bullish technical signal driven by moving averages. The ETF provides equal-weighted exposure to seven mega-cap tech stocks, though it has underperformed the S&P 500 in 2026 with a modest 2% year-to-date gain. Recent news highlights the group's focus on AI growth but notes a potential shift in market leadership away from the concentrated 'Magnificent Seven' theme.
The outlook for MAGS hinges on the continued AI-driven performance of its holdings, but risks include high concentration, valuation concerns, and market rotation. Investor sentiment is mixed, with some analysts advocating for the basket approach while others warn of fragmentation. Upside potential exists if the mega-caps reassert dominance, but diversification pressures pose a headwind.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
